within Pharmacolibrary.Drugs.ATC.S;

model S01BA15
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 1.6666666666666668e-07,
    adminDuration  = 600,
    adminMass      = 0.19 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01BA15</td></tr><td>route:</td><td>intravitreal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Fluocinolone acetonide is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It is primarily used topically for the treatment of inflammatory skin disorders and ophthalmically (e.g., intravitreal implants) to treat diabetic macular edema and non-infectious uveitis. It is approved for these uses in several markets.</p><h4>Pharmacokinetics</h4><p>No direct published pharmacokinetic (PK) models or human systemic PK parameters have been reported for fluocinolone acetonide, particularly for ophthalmic (intravitreal) administration. Systemic exposure following ophthalmic use is reported to be extremely low. The following values represent an estimation extrapolated from general corticosteroid properties and public pharmacology profiling.</p><h4>References</h4><ol><li><p>Massa, H, et al., &amp; Panos, GD (2019). Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review. <i>The Journal of international medical research</i> 47(1) 31–43. DOI:<a href=&quot;https://doi.org/10.1177/0300060518816884&quot;>10.1177/0300060518816884</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30556449/&quot;>https://pubmed.ncbi.nlm.nih.gov/30556449</a></p></li><li><p>Sadiq, MA, et al., &amp; Nguyen, QD (2015). Sustained-release fluocinolone acetonide intravitreal insert for macular edema: clinical pharmacology and safety evaluation. <i>Expert opinion on drug safety</i> 14(7) 1147–1156. DOI:<a href=&quot;https://doi.org/10.1517/14740338.2015.1041916&quot;>10.1517/14740338.2015.1041916</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25994877/&quot;>https://pubmed.ncbi.nlm.nih.gov/25994877</a></p></li><li><p>Testi, I, &amp; Pavesio, C (2019). Preliminary evaluation of YUTIQ™ (fluocinolone acetonide intravitreal implant 0.18 mg) in posterior uveitis. <i>Therapeutic delivery</i> 10(10) 621–625. DOI:<a href=&quot;https://doi.org/10.4155/tde-2019-0051&quot;>10.4155/tde-2019-0051</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31663454/&quot;>https://pubmed.ncbi.nlm.nih.gov/31663454</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01BA15;
